Literature DB >> 10880241

Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes.

E Kass1, J Parker, J Schlom, J W Greiner.   

Abstract

Repeated subcutaneous (s.c.) injections of recombinant granulocyte-macrophage colony-stimulating factor (recGM-CSF) for 4-5 days can enrich an immunization site with antigen-presenting cells (APC), which has been correlated with improved immune responses in experimental and clinical studies. A recombinant vaccinia virus encoding the GM-CSF gene (rV-GM-CSF) has been developed and can generate specific antitumour immunity in a whole tumour cell vaccine. In the present study, we examined whether rV-GM-CSF could produce and release GM-CSF locally which, in turn, might enrich a site of immunization for APC as previously shown for recGM-CSF. S.c. injection of rV-GM-CSF significantly (P<0.05) enhanced the percentage and overall number of APC, measured by class II expression levels, in the regional lymph nodes that drain the injection site. Dose- and temporal-dependent studies showed class II expression levels in the draining lymph nodes were maximally enhanced 5-7 days after a single injection of 10(7)plaque-forming units (pfu) of rV-GM-CSF. Flow cytometry revealed that the increase in class II expression resulted from (i) a higher class II expression level on CD19(+)B cells and (ii) an increase in the number of CD11c(+)/class II(+)professional APC within the draining lymph nodes. Moreover, isolation of lymph nodes from rV-GM-CSF-treated mice revealed their capacity to support higher levels of antigen-specific T cell proliferation and allospecific cytotoxic responses. A comparison between a single injection of rV-GM-CSF and a 4-day course of recGM-CSF revealed comparable changes in class II expression and functional T cell assays. GM-CSF can be delivered in a recombinant poxvirus, and the local production of the cytokine results in cellular and phenotypic changes that are similar to those of recGM-CSF. The ability to utilize rV-GM-CSF as a single inoculum may be more compatible with traditional immunization strategies. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880241     DOI: 10.1006/cyto.2000.0684

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  15 in total

1.  Multiple costimulatory modalities enhance CTL avidity.

Authors:  James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

2.  Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.

Authors:  Elizabeth K Wansley; Mala Chakraborty; Kenneth W Hance; Michael B Bernstein; Amanda L Boehm; Zhimin Guo; Deborah Quick; Alex Franzusoff; John W Greiner; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

3.  A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus.

Authors:  Celestine N Wanjalla; Elizabeth F Goldstein; Christoph Wirblich; Matthias J Schnell
Journal:  Virology       Date:  2012-02-16       Impact factor: 3.616

4.  Selective induction of apoptosis in antigen-presenting cells in mice by Parapoxvirus ovis.

Authors:  N Kruse; O Weber
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 5.  Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines.

Authors:  Kenneth W Hance; Hasan E Zeytin; John W Greiner
Journal:  Mutat Res       Date:  2005-08-25       Impact factor: 2.433

6.  Inhibition of TGF-β1 signaling promotes central memory T cell differentiation.

Authors:  Shinji Takai; Jeffrey Schlom; Joanne Tucker; Kwong Y Tsang; John W Greiner
Journal:  J Immunol       Date:  2013-07-31       Impact factor: 5.422

7.  Distinct effects of saracatinib on memory CD8+ T cell differentiation.

Authors:  Shinji Takai; Helen Sabzevari; Benedetto Farsaci; Jeffrey Schlom; John W Greiner
Journal:  J Immunol       Date:  2012-03-26       Impact factor: 5.422

Review 8.  Vaccines against human carcinomas: strategies to improve antitumor immune responses.

Authors:  Claudia Palena; Jeffrey Schlom
Journal:  J Biomed Biotechnol       Date:  2010-03-16

9.  Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.

Authors:  Benedetto Farsaci; Helen Sabzevari; Jack P Higgins; Maria Giovanna Di Bari; Shinji Takai; Jeffrey Schlom; James W Hodge
Journal:  Int J Cancer       Date:  2010-10-01       Impact factor: 7.396

10.  Chitosan solution enhances the immunoadjuvant properties of GM-CSF.

Authors:  David A Zaharoff; Connie J Rogers; Kenneth W Hance; Jeffrey Schlom; John W Greiner
Journal:  Vaccine       Date:  2007-11-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.